Preclinical data suggest that CDK function is critical for KRAS-driven tumorigenesis and that the inhibition of CDK in KRAS-mutated NSCLC leads to potent synthetic lethality [81]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.